AliveDx and Bio-Strategy have signed distribution agreements, which will enable Bio-Strategy to distribute MosaiQ® products in Australia, New Zealand, and the Pacific Islands, and Alba products in New Zealand. The distribution agreements take effect immediately.
This strategic partnership serves as a reminder of AliveDx’s unwavering dedication to developing and broadening its geographical presence. It will enable both parties to introduce new quality services to the healthcare industry and enhance patient care in the biggest markets of the Australasia and Pacific Islands regions.
“AliveDx’s partnership with Bio-Strategy is an outstanding opportunity to showcase our commitment to transform patient care worldwide and support the healthcare system through innovative, clinically relevant, accurate, and fast diagnostic solutions,” said Manuel O. Méndez, AliveDx’s CEO.
Bio-Strategy, founded in 2003, is one of the local market leaders in the Australasia region, offering a comprehensive portfolio of high-quality clinical diagnostics, laboratory equipment, consumables, chemicals, reagents, and assays for clinical laboratories, academic research, and government institutes. DKSH Group, a Switzerland-based company, recently acquired Bio-Strategy.
“We are excited to partner with AliveDx. The MosaiQ solution, an innovative microarray multiplexing diagnostic solution, will further strengthen our portfolio and enable us to provide the Australian and New Zealand healthcare markets with the latest innovative technologies. It will help us contribute to better patient outcomes,” said John Chesterfield, CEO of Bio-Strategy.
To learn more about Bio-Strategy, please visit their website.
